Archive · 25 Jul 2025
Laurus Labs Reports Significant Profit and Revenue Growth in Q1 FY26
Laurus Labs, a company in Hyderabad, made a lot more money this year!
Their profits jumped way up to ₹163 crore in the first few months of 2025-2026, compared to last year.
They also made more money overall, about 31% more.
This success is due to their CDMO business doing well and also from their other products like Generic Finished Dosage Forms.
The company is also expanding with new facilities, and the company executives plan to keep investing for more growth.
Laurus Labs' net profit increased to ₹163 crore in Q1 FY26.
Revenue for the Hyderabad-based company increased by 31% to ₹1570 crore.
The growth was fueled by contributions from the Contract Development and Manufacturing Organisation (CDMO) business.
EBITDA margins improved substantially to 24.8%.
Gross margins stood strong at 59.4% due to favorable CDMO mix and process improvement initiatives.
- Who
- Laurus Labs.
- What
- Laurus Labs' net profit increased to ₹163 crore and revenue increased to ₹1570 crore.
- When
- First quarter of fiscal year 2025-2026, ended June 30, 2025.
- Where
- Hyderabad.
- Why
- Increased contributions from CDMO business and advancement of pipeline projects, supported by Generic Finished Dosage Forms.
- Net Profit (Q1 FY26)
- ₹163 crore
- Net Profit (Q1 FY25)
- ₹13 crore
- Revenue
- ₹1570 crore
- Revenue increase
- 31%
- EBITDA Margins
- 24.8%
- Gross Margins
- 59.4%